Solasia Pharma K.K. (FRA:9SO)

Solasia Pharma K.K. Income Statement

Financials in millions JPY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	326	316	617	1,092	559	454
Revenue Growth (YoY)	239.58%	-48.78%	-43.50%	95.35%	23.13%	-65.34%
Cost of Revenue	85	131	280	430	185	209
Gross Profit	241	185	337	662	374	245
Selling, General & Admin	1,600	1,721	1,073	2,250	1,948	2,432
Research & Development	411	414	403	883	845	1,928
Operating Expenses	2,011	2,135	1,476	3,133	2,793	4,360
Operating Income	-1,770	-1,950	-1,139	-2,471	-2,419	-4,115
Interest Expense	-22	-5	-	-18	-23	-43
Interest & Investment Income	-	-	10	-	-	-
Earnings From Equity Investments	-1	-4	-5	-3	-	-
Other Non Operating Income (Expenses)	-1	-1	-1	-	-1	-2
Pretax Income	-1,794	-1,960	-1,135	-2,492	-2,443	-4,160
Income Tax Expense	2	-19	-23	56	35	-33
Net Income	-1,796	-1,941	-1,112	-2,548	-2,478	-4,127
Net Income to Common	-1,796	-1,941	-1,112	-2,548	-2,478	-4,127
Shares Outstanding (Basic)	227	199	168	152	130	117
Shares Outstanding (Diluted)	227	199	168	152	130	117
Shares Change (YoY)	21.82%	18.18%	10.62%	16.78%	10.88%	11.58%
EPS (Basic)	-7.91	-9.77	-6.61	-16.76	-19.04	-35.16
EPS (Diluted)	-7.92	-9.77	-6.62	-16.77	-19.04	-35.16
Free Cash Flow	-465	-1,034	-359	-2,074	-2,475	-2,799
Free Cash Flow Per Share	-2.05	-5.20	-2.13	-13.65	-19.02	-23.85
Gross Margin	73.93%	58.54%	54.62%	60.62%	66.91%	53.96%
Operating Margin	-542.95%	-617.09%	-184.60%	-226.28%	-432.74%	-906.39%
Profit Margin	-550.92%	-614.24%	-180.23%	-233.33%	-443.29%	-909.03%
Free Cash Flow Margin	-142.64%	-327.21%	-58.18%	-189.93%	-442.75%	-616.52%
EBITDA	-1,866	-1,755	-639	-1,937	-1,924	-3,619
EBITDA Margin	-	-	-103.57%	-177.38%	-	-
D&A For EBITDA	-96	195	500	534	495	496
EBIT	-1,770	-1,950	-1,139	-2,471	-2,419	-4,115
EBIT Margin	-	-	-184.60%	-226.28%	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.